2023
Perceived stigma related to TB preventive therapy
Palacios C, Hough M, Shrestha R, Moll A, Kompala T, Andrews L, Shenoi S. Perceived stigma related to TB preventive therapy. The International Journal Of Tuberculosis And Lung Disease 2023, 27: 209-214. PMID: 36855038, DOI: 10.5588/ijtld.22.0570.Peer-Reviewed Original ResearchConceptsTB preventative therapyTB preventive therapyAnonymous cross-sectional surveyBurden of TBCommunity-dwelling adultsRural South African communityCross-sectional surveyPreventive therapyMean agePreventative therapyEndemic settingsPatient's familyKruskal-Wallis testStigma scoresRural South AfricaPoisson regressionNovel interventionsSouth African communityTherapyLess stigmaDescriptive statisticsFamily membersStigmaTBTwo-factor solution
2019
1883. Factors Associated with Stigma Toward Isoniazid-Preventative Therapy in a Rural Community of South Africa
Palacios C, Kompala T, Moll A, Andrews L, Shenoi S. 1883. Factors Associated with Stigma Toward Isoniazid-Preventative Therapy in a Rural Community of South Africa. Open Forum Infectious Diseases 2019, 6: s51-s52. PMCID: PMC6808667, DOI: 10.1093/ofid/ofz359.113.Peer-Reviewed Original ResearchIsoniazid preventative therapyTB knowledgePresence of stigmaMarital statusPrevention of tuberculosisMultivariable linear regressionRural KwaZulu-Natal ProvinceChi-square testIPT implementationTB screeningTB transmissionHigher knowledge levelMean ageTB scoreHIV stigmaKruskal-Wallis testKnowledge scoreTuberculosisPoor knowledgeLinear regressionHIVMean scoreTotal knowledgeTherapyTreatment
2013
Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients